TY - JOUR KW - Public Health, Environmental and Occupational Health KW - Health Policy AU - Roure S AU - Pérez-Quílez O AU - Vallès X AU - Valerio L AU - Fernández-Rivas G AU - Rivaya B AU - López-Muñoz I AU - Soldevila L AU - Villanova X AU - Paredes R AU - Pedro-Botet M AU - Videla S AU - Clotet B AB -

Objectives

We sought to test the sensitivity and feasibility of a Schistosoma infection screening process consisting of a scored patient consultation questionnaire and a serological diagnostic test.

Study design

Prospective cross-sectional study.

Methods

We collected from Schistosoma-exposed individuals a 14-point check list of clinical and laboratory data related to Schistosoma infection, alongside a serological test to detect Schistosoma spp infection. A check list score was created and compared with the risk of infection and clinical recovery through an agreement analysis.

Results

Two-hundred and fifty individuals were enrolled, of whom 220 (88%) were male and 30 (12%) female. The median age was 39 (range 18–78). One hundred-fifty (60%, 95% CI 54.9%–65.1%) had a check-list score ≥2. Serology test results were positive for 142 (56.8%, 95% CI 51.6%–62%). Chronic complications compatible with long-term Schistosoma infection were detected in 29 out of these 142 (20.4%, 95% CI 13.8%–27%).,. The median score value was 3, the area under the receiver operating characteristic (ROC) curve against serology results was 0.85 and the estimated intercept check-list questionnaire score value was 1.72 (95%, CI: 1.3–2.2). Participants with a positive serological test had a substantially higher check-list score (Cohen's kappa coefficient: 0.62, 95% CI: 0.54–0.70). Ninety four percent patients empirically treated showed a subsequent improvement in clinical and laboratory parameters.

Conclusions

A two-component process consisting of a scored patient consultation questionnaire followed by serological assay can be a suitable strategy for screening populations at high risk of schistosomiasis infection.

BT - Public Health in Practice DO - 10.1016/j.puhip.2022.100245 LA - eng N2 -

Objectives

We sought to test the sensitivity and feasibility of a Schistosoma infection screening process consisting of a scored patient consultation questionnaire and a serological diagnostic test.

Study design

Prospective cross-sectional study.

Methods

We collected from Schistosoma-exposed individuals a 14-point check list of clinical and laboratory data related to Schistosoma infection, alongside a serological test to detect Schistosoma spp infection. A check list score was created and compared with the risk of infection and clinical recovery through an agreement analysis.

Results

Two-hundred and fifty individuals were enrolled, of whom 220 (88%) were male and 30 (12%) female. The median age was 39 (range 18–78). One hundred-fifty (60%, 95% CI 54.9%–65.1%) had a check-list score ≥2. Serology test results were positive for 142 (56.8%, 95% CI 51.6%–62%). Chronic complications compatible with long-term Schistosoma infection were detected in 29 out of these 142 (20.4%, 95% CI 13.8%–27%).,. The median score value was 3, the area under the receiver operating characteristic (ROC) curve against serology results was 0.85 and the estimated intercept check-list questionnaire score value was 1.72 (95%, CI: 1.3–2.2). Participants with a positive serological test had a substantially higher check-list score (Cohen's kappa coefficient: 0.62, 95% CI: 0.54–0.70). Ninety four percent patients empirically treated showed a subsequent improvement in clinical and laboratory parameters.

Conclusions

A two-component process consisting of a scored patient consultation questionnaire followed by serological assay can be a suitable strategy for screening populations at high risk of schistosomiasis infection.

PB - Elsevier BV PY - 2022 EP - 100245 T2 - Public Health in Practice TI - A simple new screening tool for diagnosing imported schistosomiasis UR - https://www.sciencedirect.com/science/article/pii/S2666535222000210/pdfft?md5=68ef4c068704dbad466441e0af71d369&pid=1-s2.0-S2666535222000210-main.pdf VL - 3 SN - 2666-5352 ER -